In patients with colorectal peritoneal metastases, cytoreductive surgery has shown significant survival benefits, regardless of the use of intraperitoneal chemotherapy. Despite recent challenges to the efficacy of intraperitoneal treatments, the comprehensive review indicates that surgical intervention remains a crucial component in managing this aggressive form of cancer. The study emphasizes a critical analysis of current […]
Category: Cytoreductive Surgery & Peritoneum
Cytoreductive surgery with HIPEC improves survival in CRC patients.
A systematic review and meta-analysis encompassing 14 studies reveal that colorectal cancer patients with peritoneal metastases experience enhanced overall survival (OS) and relapse-free survival (RFS) following cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Compared to control regimens, the CRS + HIPEC approach markedly improves these outcomes, shedding light on effective therapeutic strategies for […]
Surgical complications from CRS and HIPEC in cancer patients
A narrative review assessed complications linked to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients battling peritoneal metastasis. It cataloged categories of complications, including surgical, chemotherapy-related, and systemic issues, emphasizing the high morbidity associated with these interventions. The findings advocate for stringent patient selection, precise surgical techniques, and robust intraoperative care. Interdisciplinary collaboration is highlighted […]
Multisocietal consensus supports CRS and HIPEC for DMPM patients
A multisocietal consensus has endorsed cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating diffuse malignant peritoneal mesothelioma (DMPM). An expert panel, acknowledging the limited efficacy of systemic chemotherapy, strongly recommended this approach for a select subgroup of patients. Despite low evidence certainty, the panel emphasized the potential for improved survival outcomes with CRS-HIPEC, […]
Cytoreductive surgery enhances survival in colorectal cancer patients.
A bicentric analysis revealed that patients with colorectal cancer peritoneal metastases (crpm), particularly when isolated or with limited extraperitoneal metastases (epm), experience significantly improved median overall survival (58 months vs. 39 months) following cytoreductive surgery. The study involved 413 patients, demonstrating similar postoperative outcomes between those with and without epm. Notably, specific prognostic groups identified […]
CRS/HIPEC improves survival in small bowel adenocarcinoma patients
A systematic review and meta-analysis of 746 patients revealed that cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) significantly enhances median overall survival to 32.3 months, compared to 14.5 months with systemic chemotherapy alone. In patients undergoing complete cytoreduction, the study reported a major morbidity rate of 20.7% and a mortality rate of 1.7% associated with CRS/HIPEC. […]
Screening improves survival outcomes in colorectal peritoneal metastases.
Analysis of 2,773 colorectal peritoneal metastasis patients revealed that those diagnosed through screening had significantly better survival rates and more often received curative treatment. Specifically, 7% were screen-detected, with a median overall survival of 20 months compared to 10.8 months for clinically detected patients. Additionally, 28% of screen-detected patients underwent cytoreductive surgery with hyperthermic intraperitoneal […]
Enhanced Recovery After Surgery Program Lowers Hospital Stays
A multidisciplinary Enhanced Recovery After Surgery (ERAS) program significantly improved compliance and reduced hospital stays for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Compliance with ERAS protocols rose from 32.8% to 70.8%. Concurrently, the median length of stay decreased from 14 to 9 days, with no significant difference in major morbidity or 30-day […]
Hyperthermic Intraperitoneal Chemotherapy Enhances Survival in Gastric Cancer
A meta-analysis of 12 randomized controlled trials involving 1,181 gastric cancer patients demonstrated that hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improved survival rates compared to control groups at 1, 2, 3, and 5 years. The recurrence rates were notably lower in the HIPEC group, and higher disease-free survival rates were also observed. These findings suggest that […]
Circulating biomarkers predict peritoneal metastasis in gastric cancer
A prospective clinical study evaluates the predictive effects of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in peritoneal lavage fluid for metachronous peritoneal metastasis (PM) in gastric cancer patients following radical resection. A total of 200 patients will be monitored over two years, with a primary focus on PM incidence one year post-surgery. […]